Pegsunercept

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.

Pegsunercept

Clinical data
Routes of administration	subcutaneous injection
ATC code	none
Legal status
Legal status	investigational
Pharmacokinetic data
Bioavailability	N/A
Identifiers
CAS Number	330988-75-5^N
ChemSpider	none
UNII	Q5I7SFZ853
KEGG	D05393^Y
Chemical and physical data
Formula	C502H758N154O165S16
Molar mass	12,103 g/mol (protein part) g·mol^−1
^NY (what is this?)  (verify)

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]

References

1. Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
2. Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
3. Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M (December 2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–10. PMID 16331754.